530
|
SEPTEMBER 2014
|
VOLUME 11
www.nature.com/nrurol
11. Bhasin, S.
et al.
The effects of supraphysiologic
doses of testosterone on muscle size and
strength in normal men.
N. Engl. J. Med.
335
,
1–7 (1996).
12. Morgentaler, A., Bruning, C. O. 3
rd
&
DeWolf, W. C. Occult prostate cancer in men
with low serum testosterone levels.
JAMA
276
,
1904–1906 (1996).
13. Labrie, F.
et al.
Serum prostate specific antigen
as pre-screening test for prostate cancer.
J.
Urol.
147
, 846–851 (1992).
14. Cooner, W. H.
et al.
Prostate cancer detection in
a clinical urological practice by ultrasonography,
digital rectal examination, and prostate-specific
antigen.
J.
Urol.
143
, 1146–1150 (1990).
15. Seaman, E.
et al.
PSA density (PSAD).
Urol.
Clin.
North
Am.
20
, 653–663 (1993).
16. Hoffman, M. A., DeWolf, W. C. & Morgentaler, A.
Is low serum free testosterone a marker
for high grade prostate cancer?
J. Urol.
163
,
824–827 (2000).
17. Schatzl, G.
et al.
High-grade prostate cancer is
associated with low serum testosterone levels.
Prostate
47
, 52–58 (2001).
18. Isom-Batz, G.
et al.
Testosterone as a predictor
of pathological stage in clinically localized
prostate cancer.
J. Urol.
173
, 1935–1937
(2005).
19. Mearini, L.
et al.
Low serum testosterone levels
are predictive of prostate cancer.
World J. Urol.
31
, 247–252 (2013).
20. Massengill, J. C.
et al.
Pretreatment total
testosterone level predicts pathological stage
in patients with localized prostate cancer
treated with radical prostatectomy.
J. Urol.
169
,
1670–1675 (2003).
21. Teloken, C.
et al.
Low serum testosterone levels
are associated with positive surgical margins
in radical retropubic prostatectomy:
hypogonadism represents bad prognosis
in prostate cancer.
J. Urol.
174
, 2178–2180
(2005).
22. Yamamoto, S.
et al.
Preoperative serum
testosterone level as an independent predictor
of treatment failure following radical
prostatectomy.
Eur. Urol.
52
, 696–701 (2007).
23. Kim, H. S., Lee, C. Y., Lim, D. H., Kim, C. S.
& Baik, S. The prostate cancer detection rate
on the second prostate biopsy according to
prostate-specific antigen trend.
Korean J. Urol.
53
, 686–690 (2012).
24. Ribeiro, M., Ruff, P. & Falkson, G. Low serum
testosterone and a younger age predict for
a poor outcome in metastatic prostate cancer.
Am. J. Clin. Oncol.
20
, 605–608 (1997).
25. Calof, O. M.
et al.
Adverse events associated
with testosterone replacement in middle-aged
and older men: a meta-analysis of randomized,
placebo-controlled trials.
J. Gerontol. A Biol. Sci.
Med. Sci.
60
, 1451–1457 (2005).
26. Hsing, A. W. Hormones and prostate cancer:
what’s next?
Epidemiol. Rev.
23
, 42–58 (2001).
27. Garcia-Cruz, E.
et al.
Low testosterone level
predicts prostate cancer in re-biopsy in patients
with high grade prostatic intraepithelial
neoplasia.
BJU Int.
110
, E199–E202 (2012).
28. Rhoden, E. L. & Morgentaler, A. Testosterone
replacement therapy in hypogonadal men at
high risk for prostate cancer: results of
1 year of treatment in men with prostatic
intraepithelial neoplasia.
J. Urol.
170
,
2348–2351 (2003).
29. Pastuszak, A. W.
et al.
Testosterone
replacement therapy in patients with prostate
cancer after radical prostatectomy.
J. Urol.
190
,
639–644 (2013).
30. Sarosdy, M. F. Testosterone replacement for
hypogonadism after treatment of early prostate
cancer with brachytherapy.
Cancer
109
,
536–541 (2007).
31. Pastuszak, A. W.
et al.
Testosterone
replacement therapy in the setting of prostate
cancer treated with radiation.
Int. J. Impot. Res.
25
, 24–28 (2013).
32. Kaufman, J. M. & Graydon, R. J. Androgen
replacement after curative radical
prostatectomy for prostate cancer in
hypogonadal men.
J. Urol.
172
, 920–922
(2004).
33. Khera, M.
et al.
Testosterone replacement
therapy following radical prostatectomy.
J. Sex.
Med.
6
, 1165–1170 (2009).
34. Morales, A., Black, A. M. & Emerson, L. E.
Testosterone administration to men with
testosterone deficiency syndrome after
external beam radiotherapy for localized
prostate cancer: preliminary observations.
BJU Int.
103
, 62–64 (2009).
35. Agarwal, P. K. & Oefelein, M. G. Testosterone
replacement therapy after primary treatment
for prostate cancer.
J. Urol.
173
, 533–536
(2005).
36. van Oort, I. M., Kok, D. E., Kiemeney, L. A.,
Hulsbergen-van de Kaa, C. A. & Witjes, J. A.
A single institution experience with biochemical
recurrence after radical prostatectomy for
tumors that on pathology are of small volume
or “insignificant”.
Urol. Oncol.
27
, 509–513
(2009).
37. Morales, A. Effect of testosterone
administration to men with prostate cancer
is unpredictable: a word of caution and
suggestions for a registry.
BJU Int.
107
,
1369–1373 (2011).
38. Khera, M.
et al.
Changes in prostate specific
antigen in hypogonadal men after 12 months
of testosterone replacement therapy: support
for the prostate saturation theory.
J. Urol.
186
,
1005–1011 (2011).
Author contributions
All authors researched the data for the article, made
substantial contributions to discussion of content
and reviewed/edited the manuscript before
submission. J.M.D., G.M.L., and L.I.L. contributed
to writing the article.
PERSPECTIVES
© 2014 Macmillan Publishers Limited. All rights reserved